Differential Expression of Metabotropic Glutamate Receptors 2 and 3 in Schizophrenia: A Mechanism for Antipsychotic Drug Action?
- 1 July 2009
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 166 (7), 812-820
- https://doi.org/10.1176/appi.ajp.2009.08091445
Abstract
Objective: Preclinical and clinical data implicate the group II metabotropic glutamate receptors mGluR2 and mGluR3 in the pathophysiology of schizophrenia. Moreover, a recent phase II clinical trial demonstrated the antipsychotic efficacy of a mGluR2/mGluR3 agonist. The purpose of the present study was to distinguish the expression of mGluR2 and mGluR3 receptor proteins in schizophrenia and to quantify glutamate carboxypeptidase II (GCP II) in order to explore a role for the metabotropic receptors in schizophrenia therapeutics. GCP II is an enzyme that metabolizes N -acetyl-aspartyl-glutamate (NAAG), which is the only known specific endogenous agonist of mGluR3 in the mammalian brain. Method: The normal expression levels of mGluR2, mGluR3, and GCP II were determined for 10 regions of the postmortem human brain using specific antibodies. Differences in expression levels of each protein were examined in the dorsolateral prefrontal cortex, temporal cortex, and motor cortex in 15 postmortem schizophrenia subjects and 15 postmortem matched normal comparison subjects. Chronic antipsychotic treatment in rodents was conducted to examine the potential effect of antipsychotic drugs on expression of the three proteins. Results: Findings revealed a significant increase in GCP II protein and a reduction in mGluR3 protein in the dorsolateral prefrontal cortex in schizophrenia subjects, with mGluR2 protein levels unchanged. Chronic antipsychotic treatment in rodents did not influence GCP II or mGluR3 levels. Conclusions: Increased GCP II expression and low mGluR3 expression in the dorsolateral prefrontal cortex suggest that NAAG-mediated signaling is impaired in this brain region in schizophrenia. Further, these data implicate the mGluR3 receptor in the antipsychotic action of mGluR2/mGluR3 agonists.Keywords
This publication has 39 references indexed in Scilit:
- NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluRJournal of Neurochemistry, 2004
- Complexity of Prefrontal Cortical Dysfunction in Schizophrenia: More Than Up or DownAmerican Journal of Psychiatry, 2003
- Glutamate Carboxypeptidase II Gene Expression in the Human Frontal and Temporal Lobe in SchizophreniaNeuropsychopharmacology, 2003
- Regulation of Glutamate Carboxypeptidase II Function in Corticolimbic Regions of Rat Brain by Phencyclidine, Haloperidol, and ClozapineNeuropsychopharmacology, 2002
- Modulation of Group II Metabotropic Glutamate Receptor Signaling by Chronic CocaineJournal of Pharmacology and Experimental Therapeutics, 2002
- BMP-7 and Excess Glutamate: Opposing Effects on Dendrite Growth from Cerebral Cortical Neurons in VitroExperimental Neurology, 2002
- Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjectsMolecular Psychiatry, 2002
- Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sitesNeuroscience, 2001
- Relation of Prefrontal Cortex Dysfunction to Working Memory and Symptoms in SchizophreniaAmerican Journal of Psychiatry, 2001
- N‐AcetylaspartylglutamateJournal of Neurochemistry, 2000